Shares of Insmed Incorporated (NASDAQ:INSM – Get Free Report) have been given a consensus rating of “Buy” by the sixteen ...

The Novato-based maker of biopharmaceutical treatments for rare diseases plans to release this year a new gene therapy for ...

The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Vilobelimab is being developed for various debilitating or life-threatening inflammatory indications, including a Phase 3 trial for pyoderma gangrenosum (PG). Vilobelimab has been granted orphan drug ...

This week's issue of Rubber News features our special report on the energy, oil and gas industries, including a deeper look ...

Ieq Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) during the ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

The global microbiology culture market propelled by increasing demand across sectors such as pharmaceuticals, food and ...

(NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) ...

Praxis on Friday said the independent data monitoring committee overseeing an interim analysis of Study 1 of the "Essential3" program has recommended that the study be stopped for futility because it ...